Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy

References

• Al Zaid Siddiquee K, Turkson J. 2008. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18:254–267.
   PubMed Web of Science ®Google Scholar
• Baguley BC. 2010. Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316.
   PubMed Web of Science ®Google Scholar
• Bosch-Barrera J, Menendez JA. 2015. Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev. 41:540–546.
   PubMed Web of Science ®Google Scholar
• Cheung CW, Gibbons N, Johnson DW, Nicol DL. 2010. Silibinin-a promising new treatment for cancer. Anticancer Agents Med Chem. 10:186–195.
   PubMed Web of Science ®Google Scholar
• Chou TC. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446.
   PubMed Web of Science ®Google Scholar
• Comelli MC, Mengs U, Schneider C, Prosdocimi M. 2007. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 6:120–129.
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. 2007. MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
   PubMed Web of Science ®Google Scholar
• Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. 2014. Breast cancer statistics and markers. J Cancer Res Ther. 10:506–511.
   PubMed Web of Science ®Google Scholar
• Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G, Choi KS. 2005. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene. 24:4765–4777.
   PubMed Web of Science ®Google Scholar
• Falamarzian A, Aliabadi HM, Molavi O, Seubert JM, Lai R, Uludag H, Lavasanifar A. 2014. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. J Biomed Mater Res A. 102:3216–3228.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. 1989. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 9:105–113.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, et al. 2010. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 70:848–855.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM. 2007. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 25:139–146.
   PubMed Web of Science ®Google Scholar
• Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, et al. 2006. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 12:2944–2950.
   PubMed Web of Science ®Google Scholar
• Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, Lee ES, Park JH, Yun CH, Chung JU, Lee KJ, et al. 2015 . Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res. 75:1691–1702.
   PubMed Web of Science ®Google Scholar
• Kauntz H, Bousserouel S, Gosse F, Marescaux J, Raul F. 2012. Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis. Int J Oncol. 41:849–854.
   PubMed Web of Science ®Google Scholar
• Kil WH, Kim SM, Lee JE, Park KS, Nam SJ. 2014. Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells. Ann Surg Treat Res. 87:167–173.
   PubMed Web of Science ®Google Scholar
• Kondo T. 2007. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark. 3:245–250.
   PubMedGoogle Scholar
• Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, Kelly KM. 2010. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 116:506–513.
   PubMed Web of Science ®Google Scholar
• Molavi O, Samadi N, Wu C, Lavasanifar A, Lai R. 2016. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. Leuk Lymphoma. 57:1154–1162.
   PubMed Web of Science ®Google Scholar
• Molavi O, Wang P, Zak Z, Gelebart P, Belch A, Lai R. 2013. Gene methylation and silencing of SOCS3 in mantle cell lymphoma. Br J Haematol. 161:348–356.
   PubMed Web of Science ®Google Scholar
• Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Ramirez G, Aguilar C, Montgomery K, Morbidoni L, Arterburn JM, et al. 2000. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evid Rep Technol Assess (Summ). 4:1–3.
   Google Scholar
• Mundi PS, Sachdev J, McCourt C, Kalinsky K. 2016. AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol. 82:943–956.
   PubMed Web of Science ®Google Scholar
• Navolanic PM, Steelman LS, McCubrey JA. 2003. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol. 22:237–252.
   PubMed Web of Science ®Google Scholar
• Orlandi L, Bearzatto A, Abolafio G, De Marco C, Daidone MG, Zaffaroni N. 1999. Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer. 81:252–260.
   PubMed Web of Science ®Google Scholar
• Pirouzpanah MB, Sabzichi M, Pirouzpanah S, Chavoshi H, Samadi N. 2015. Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways. Asian Pac J Cancer Prev. 16:2087–2092.
   PubMedGoogle Scholar
• Raina K, Agarwal R. 2007. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin. 28:1466–1475.
   PubMed Web of Science ®Google Scholar
• Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. 2002. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 21:7611–7618.
   PubMed Web of Science ®Google Scholar
• Scully OJ, Bay BH, Yip G, Yu Y. 2012. Breast cancer metastasis. Cancer Genomics Proteomics. 9:311–320.
   PubMed Web of Science ®Google Scholar
• Sharifi S, Barar J, Hejazi MS, Samadi N. 2014. Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel. Asian Pac J Cancer Prev. 15:8617–8622.
   PubMedGoogle Scholar
• Singh RP, Raina K, Sharma G, Agarwal R. 2008. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 14:7773–7780.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, et al. 2011. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 10:3003–3015.
   PubMed Web of Science ®Google Scholar
• Syed SB, Coumar MS. 2016 . P-Glycoprotein mediated multidrug resistance reversal by phytochemicals: a review of SAR future perspective for drug design. Curr Top Med Chem. 16:2484–2508.
   PubMed Web of Science ®Google Scholar
• Tan FH, Putoczki TL, Stylli SS, Luwor RB. 2014. The role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr Drug Targets. 15:1341–1353.
   PubMed Web of Science ®Google Scholar
• Ting H, Deep G, Agarwal R. 2013. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 15:707–716.
   PubMed Web of Science ®Google Scholar
• Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. 2004. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 3:261–269.
   PubMed Web of Science ®Google Scholar
• Tyagi AK, Agarwal C, Chan DC, Agarwal R. 2004. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 11:493–499.
   PubMed Web of Science ®Google Scholar
• Wang X, Crowe PJ, Goldstein D, Yang JL. 2012. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol. 41:1181–1191.
   PubMed Web of Science ®Google Scholar
• Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, et al. 2015. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood. 126:336–345.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhang J, Wang P, Ye X, Jung K, Bone KM, Pearson JD, Ingham RJ, McMullen TP, Ma Y, et al. 2012. Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. Cell Signal. 24:1989–1998.
   PubMed Web of Science ®Google Scholar
• Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, et al. 2013 . Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 25:2625–2633.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ge Y, Chen Y, Li Q, Chen J, Dong Y, Shi W. 2012. Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem Funct. 30:243–248.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu P, Chen B, Wang Y, Wang X, Chiriva Internati M, Wachtel MS, Frezza EE. 2008. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res. 28:1119–1127.
   PubMed Web of Science ®Google Scholar